US011311605B2

(12) **United States Patent**
Kraynov et al.

(10) **Patent No.: US 11,311,605 B2**
(45) **Date of Patent: *Apr. 26, 2022**

(54) **METHODS OF TREATING HEART FAILURE AND FIBROTIC DISORDERS USING MODIFIED RELAXIN POLYPEPTIDES**

(71) Applicant: **AMBRX, INC.**, La Jolla, CA (US)

(72) Inventors: **Vadim Kraynov**, San Diego, CA (US); **Nick Knudsen**, Escondido, CA (US); **Amha Hewet**, San Diego, CA (US); **Kristine De Dios**, San Diego, CA (US); **Jason Pinkstaff**, Carlsbad, CA (US); **Lorraine Sullivan**, San Diego, CA (US)

(73) Assignee: **AMBRX, INC.**, La Jolla, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/884,639**

(22) Filed: **May 27, 2020**

(65) **Prior Publication Data**

US 2020/0360485 A1 Nov. 19, 2020

Related U.S. Application Data

(60) Division of application No. 16/285,986, filed on Feb. 26, 2019, now Pat. No. 10,751,391, which is a division of application No. 15/386,347, filed on Dec. 21, 2016, now Pat. No. 10,253,083, which is a division of application No. 13/774,349, filed on Feb. 22, 2013, now Pat. No. 9,567,386, which is a continuation-in-part of application No. 13/212,101, filed on Aug. 17, 2011, now Pat. No. 8,735,539.

(60) Provisional application No. 61/374,582, filed on Aug. 17, 2010.

(51) **Int. Cl.**

A61K 38/18	(2006.01)
A61K 38/22	(2006.01)
C07K 14/64	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/2221*** (2013.01); ***C07K 14/64*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,773,919	A	11/1973	Boswell et al.
4,289,872	A	9/1981	Denkewalter et al.
4,412,989	A	11/1983	Iwashita et al.
4,414,148	A	11/1983	Jansen et al.
4,485,045	A	11/1984	Regen
4,511,502	A	4/1985	Builder et al.
4,511,503	A	4/1985	Olson et al.
4,512,922	A	4/1985	Jones et al.
4,544,545	A	10/1985	Ryan et al.
4,551,433	A	11/1985	Deboer
4,569,789	A	2/1986	Blattler et al.
4,619,794	A	10/1986	Hauser
4,659,839	A	4/1987	Nicolotti et al.
4,670,417	A	6/1987	Iwasaki et al.
4,671,958	A	6/1987	Rodwell et al.
4,680,338	A	7/1987	Sundoro
4,689,406	A	8/1987	Banks et al.
4,699,784	A	10/1987	Shih et al.
4,738,921	A	4/1988	Belagaje et al.
4,755,465	A	7/1988	Gray et al.
4,837,148	A	6/1989	Cregg
4,859,600	A	8/1989	Gray et al.
4,876,197	A	10/1989	Burke et al.
4,880,734	A	11/1989	Burke et al.
4,902,502	A	2/1990	Nitecki et al.
4,904,584	A	2/1990	Shaw
4,929,555	A	5/1990	Cregg et al.
5,021,234	A	6/1991	Ehrenfeld
5,089,398	A	2/1992	Rosenberg et al.
5,122,614	A	6/1992	Zalipsky
5,145,962	A	9/1992	Hudson et al.
5,162,601	A	11/1992	Slightom
5,219,564	A	6/1993	Zalipsky et al.
5,229,490	A	7/1993	Tam
5,231,178	A	7/1993	Holtz et al.
5,252,714	A	10/1993	Harris et al.
5,281,698	A	1/1994	Nitecki
5,290,686	A	3/1994	Kendal et al.
5,324,639	A	6/1994	Brierley et al.
5,324,844	A	6/1994	Zalipsky
5,382,657	A	1/1995	Karasiewicz et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2707840	2/2009
DE	3218121	11/1983

(Continued)

OTHER PUBLICATIONS

Zhongming Tang, "Biotechnology Drugs—Introduction and Practical Handbook", Chemical Industry Press, Jan. 2008.

(Continued)

Primary Examiner — Christine J Saoud

(74) *Attorney, Agent, or Firm* — Robin L. Teskin; Baker, Donelson, Bearman, Caldwell & Berkowitz PC

(57) **ABSTRACT**

Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.

24 Claims, 30 Drawing Sheets

Specification includes a Sequence Listing.